allergic disorders. Studying the role of the microbiome and how it interacts with the host will provide opportunities to better understand the complex disease process of asthma.
The development of micro-organism identification technologies from culture-dependent to DNA/RNA sequencing technologies has made more in-depth microbiome research possible. The focus shifted to a wider prospective, including both commensal and pathogenic micro-organisms and their interaction with the human body and their role in asthma. To date, several cross-sectional and longitudinal microbiome studies have been conducted in asthmatics with different phenotypes, which have revealed many associations between bacterial composition and asthma. However, further research is still needed to reach definitive conclusions.
In this review, we aim to provide an overview of methodological aspects of conducting asthma microbiome studies. In addition, we will explore the associations and role of bacterial microbiota in asthma and discuss the challenges that hinder appropriate interpretation of the results and transfer of knowledge into clinical practice.
| ME THODOLOG I C AL A S PEC TS OF A S THMA MI CROB I OME S TUD IE S

| Sampling of the microbiome
The first step in the analysis of the microbiome is to obtain samples.
Samples for analysis of the microbiome in relation to asthma either originate from the naso-/oropharyngeal route (such as nose, throat), airways or from the large intestinal tract (gut). Table 1 represents commonly used sampling compartments, and their main advantages and disadvantages.
Since many different sampling compartments and methods are currently used, [14] [15] [16] [17] [18] obtained results are difficult to compare. For example, a study conducted in 39 asthmatics and 19 healthy controls revealed that statistically significant differences in bacterial α-diversity (diversity in individual site or sample) and β-diversity (intervariability, between sites or samples) were found between bronchial brushings and bronchoalveolar lavage (BAL) fluid within individuals for both asthmatics and control groups. 14 In a study of 30 asthmatic children, significant differences in bacterial α-and β-diversity were found between nasal brushes and nasal washes within individuals. 15 In another study comparing bacterial composition in bronchial aspirates and bronchial brushings in 13 adults with severe asthma, the composition of the microbiota in the bronchial brushings showed a specific pattern that was not represented in bronchial aspirates. 16 Induced sputum was found to be more compositionally similar to bronchial brushings than oral washes or nasal brushings in adult atopic asthmatics (n = 22). 17 A study conducted in 60 individuals comparing stool samples with rectal swabs found that certain bacterial taxa are highly specific to the sample site, while other taxa can be found in both sample types and are specific for the individual. 18 Although the choice of the sampling compartments in studies depends on several factors such as patients' age, disease state and available facilities, it is of importance to note that microbial communities can change between sampling compartments within the same individual, for example mucosa-associated or luminal bacteria. In
TA B L E 1 Microbiome sampling compartments, advantages and disadvantages
Route
Sampling compartment Advantages Disadvantages
Naso-/oropharyngeal route and airways
Nasal swab or wash Non-invasive, high patient acceptability, easy to sample frequently Patients may feel slightly uncomfortable As it only represents the upper respiratory tract, it may not be suitable if the study aim was to characterize the lower respiratory microbiome Saliva, buccal swab or wash Non-invasive, high patient acceptability, easy to sample frequently Differences related to gender, pH and diet intake should be accounted for Sputum (spontaneous or induced)
Relatively non-invasive, can represent microbiota from the lower respiratory tract
May be cross-contaminated from bacteria from the saliva or oral cavity, patient's cooperation is required to assure the quality of sample Bronchoalveolar lavage and bronchial aspirates
Good representation of the microbiota from the lower respiratory tract
Invasive, less patient acceptability, risk of cross-contamination during aspiration
Bronchial brushings and biopsies
Good representation of the microbiota from the lower respiratory tract, including mucosa-associated microbiota Invasive, less patient acceptability
Gut
Stool
Non-invasive Patient might feel uncomfortable collecting stool samples
Rectal swab Non-invasive, easy to sample frequently
Patients may feel more discomfort than stool samples, patient acceptability may be low, may be cross-contaminated by bacteria from the skin addition, it is very important to consider the effect introduced by treatment with drugs on the microbiome present in different sampling compartments. For instance, studies have shown that medications such as proton pump inhibitors, antibiotics, antidepressants, statins, antidiabetics and probably others can influence gut microbiota.
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| Available microbiome analysis techniques
Various techniques are available to analyse the microbiome (Table   S1 ). In the past, microbial studies in asthma were dependent on the growth of the micro-organisms on laboratory culture media, which was limited to certain pathogenic micro-organisms.
More recent studies have shown that culture-based methods are relatively insensitive to detect certain micro-organisms, such as atypical bacteria. 21, 22 Therefore, other techniques have been used such as serologic testing, which depends on identifying antibodies against a pathogen, for example microimmunofluorescence or ELISA. 23, 24 Newer methods, which target DNA of a pathogen, such as PCR and reverse transcriptase PCR, have been used in microbiome asthma studies, [25] [26] [27] with some commercially available PCR kits for detecting certain pathogens. 28, 29 With the emergence of novel nucleotide sequencing technologies, microbiome research shifted from a single pathogenic microorganism to a microbial community-oriented approach, studying commensal and pathogenic bacteria and their interactions. Cultureindependent or sequencing techniques start with the extraction of the nucleic acid (DNA and/or RNA) of the collected samples and can be subdivided into amplicon sequencing or whole-genome shotgun (WGS) sequencing.
Amplicon sequencing of the 16S ribosomal RNA (rRNA) of the microbiome is one of the most common techniques used recently in microbiome asthma studies. 16S rRNA is found in all bacteria and archaea, and is ideal for classifying micro-organisms. There are nine separate hypervariable regions (V1-V9) within the 16S rRNA gene 30 that are targeted by the sequencing platforms. On the other hand, WGS sequencing depends on fragmentation and random sequencing of the totally extracted microbiome DNA. It has been reported that WGS sequencing has improved accuracy and provides better detection of microbial species when compared to 16S amplicon sequencing. 31 Moreover, WGS sequencing provides the opportunity to assess the functional characteristics of the microbiome because it targets the whole genome instead of particular regions. However, it is more expensive and requires higher computational power than amplicon sequencing, and is therefore less used.
Various sequencing platforms are available which differ based on the read length, sequencing depth and error rates. 32 The In addition to the methodological aspects we discussed, we recommend reading a recently published article that highlights the best methodological practices that should be taken into account in the microbiome respiratory research such as quality control, data handling, microbial contamination, low biomass samples and standardized protocols. 36 
| L ATE S T IN S I G HTS INTO MI CROB IAL DYS B I OS IS AND A S THMA PHENOT YPE S (S EQUEN CING S TUDIE S)
Samples for high-throughput microbiome sequencing studies in asthma patients are either taken at a certain time-point of patients' life (cross-sectional studies) or at two or more time-points (longitudinal studies).
| Cross-sectional studies
Various cross-sectional studies have studied associations between airway or gut bacterial dysbiosis at single time-points in relation to asthma phenotypes, for example mild-moderate, severe, and uncontrolled asthma or inflammatory phenotypes, such as eosinophilic and neutrophilic asthma. Most of the studies compared the microbial compositions between asthmatics with different severity levels and healthy controls, and sometimes with other airway disorders, such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Table 2 summarizes the main findings of airway microbiome cross-sectional studies conducted in asthmatic patients.
Regarding airway bacterial composition, various studies have shown that Proteobacteria, particularly Haemophilus species, are more common in asthmatic patients, while Bacteroidetes and Actinobacteria are more common in healthy controls. [37] [38] [39] [40] [41] [42] [43] However, it is not clear whether this difference in bacterial composition is a feature of asthma itself, related to corticosteroid use, or both.
For example, there was an increase in the relative abundance of Proteobacteria and decrease in the abundance of Bacteroidetes and Fusobacteria in endobronchial brushings samples with increasing corticosteroid use. 14 Furthermore, it was reported that there were no differences in microbial compositions at phyla level between healthy controls and corticosteroid-free asthma patients. 44 A possible explanation for the effect of corticosteroids on microbiota is that they suppress or disturb mucosal immune system and therefore lead to overgrowth of bacteria. This overgrowth probably leads to harmful health effects if opportunistic or pathogenic micro-organisms became abundant such as fungal candidiasis associated with the use of inhaled corticosteroids. 45 However, it may still lead to beneficial effects by increasing abundances of beneficial commensal bacteria. 46 The results of other studies may reflect that corticosteroids are not the only influencers of the bacterial compositions. [47] [48] [49] other groups. 47 In the same study, atopic asthmatic patients were further randomized into fluticasone arm versus placebo which later revealed that corticosteroids may cause changes in certain bacteria. 47 In another study of 23 corticosteroid-free asthma patients and 10 healthy controls, bacterial dysbiosis was found between asthma patients with a low level of eosinophils when compared with asthma patients with high levels of eosinophils and healthy controls. 48 This suggests that asthma disease by itself, different phenotypes, and medications used (including corticosteroids) play a significant role in shaping the microbiome profiles.
Regarding bacterial diversity, some studies have shown that asthma patients had higher bacterial diversity in the airways when compared to healthy controls. 38, 39 Again, this might be related to the effect of corticosteroids, which by suppressing immunity would enhance the growth of diverse microbiota. However, in other studies, no significant differences in bacterial diversity were found between asthma patients and healthy controls. 43, 44, 50 Other studies showed that asthmatic patients had lower airway and gut microbiome diversity when compared to healthy controls. [51] [52] [53] Inflammatory phenotypes of asthma have been shown to be associated with airway bacterial dysbiosis. Three studies have reported that neutrophilic asthma patients had lower sputum bacterial richness and diversity and showed higher abundances of 62 and age groups. 43 Moreover, it should be noted that sample size is a huge determining factors for inconsistencies found in reported microbiome statistical differences which should be considered while designing the microbiome asthma studies.
In conclusion, there is no distinct microbiome profile that can be said to be responsible for or associated with the asthma disease process. Under the umbrella of inconsistencies in reported results, several factors might hold responsible such as different populations, environments, age groups, drugs, diet and study design.
| Longitudinal studies
In longitudinal microbiome studies, patients have been followed prospectively to study associations between early life microbial dysbiosis and asthma development later in life or changes in the microbiome composition between two time-points (Table 3) . Often the gut microbiome in children has been investigated in this type of studies. A recent study showed that an immature gut microbiome profile at 1 year of age in children born to asthmatic mothers was associated with asthma development at 5 years of age. 63 However, another study showed that children who developed asthma at 7 years of age (n = 8) had distinct gut bacterial profiles at one week and one month, but not at one year of age. 64 Similarly, it was shown that during the first three months of life, children with high risk of asthma had lower abundances of certain bacteria genera in their stool compared to others. 65, 66 A different study showed that there was an association between gut bacterial diversity at 1 month and 1 year of age and allergic sensitization, but not with asthma development until 6 years of age. 67 Only limited studies are available studying early life airway bacterial composition and the risk of developing asthma. One study showed that chronic wheeze at 5 years of age was associated with early airway colonization with Streptococcus during the first year of life. 68 In another study, cultures from the hypopharyngeal region aspirates of 321 infants at 1 month showed that colonization with Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrhalis increased the risk for recurrent wheeze and asthma at 5 years of age. 69 Despite that there was inconsistency about the most important time period (whether the first 3 months or the first year of life) to shape asthma risk later in life, it is apparent that gut or airway microbiota disturbances at an early age, especially the first year of life, are risk factors for asthma development. This bacterial dysbiosis may explain why early life antibiotic exposure may increase risk of later asthma development. [70] [71] [72] In conclusion, longitudinal microbiome studies may help to uncover the shifts that occur in microbiome profiles over time. Studying the time-associated changes in the microbiome is essential because the microbiome is dynamic by nature and is influenced by several environmental and biological conditions. In addition to the studies that investigate early life microbial dysbiosis and its relation to asthma risk, more longitudinal investigation should be also conducted in patients ing the first year of life during both healthy condition and episodes of acute respiratory infections, on allergic sensitization at 2 y and chronic wheeze at 5 and 10 y of age Children who had atopy by age of 2 y and developed chronic wheeze at 5 y of age were twice likely to have early colonization with Streptococcus, and lower respiratory tract infection during the first year of life compared to those who did not develop wheezing (Continues) with already established asthma disease to uncover the dynamic relation between the microbiome and the asthma disease process.
| HOW C AN THE MI CROB I OME INFLUEN CE A S THMA DE VELOPMENT ?
Various studies have found associations between microbial dysbiosis in the airways and/or intestinal tract and the risk of asthma development;
however, the causal relationship remains unclear. In this section, we discuss two different processes, which may explain how the microbiome might influence asthma risk and the evidence supporting them.
| From hygiene hypothesis to old friends theory
The "hygiene hypothesis" that was first developed by Strachan et al assumes that excessive cleanliness, vaccination and antibiotic use can lead to an over-reactive immune system. 73, 74 It was suggested that too much hygiene lowers the threshold of immune adaptation, it becomes sensitive and it over-reacts to substances that are normally not recognized by the immune system, like pollen and other allergens. In contrast, more exposure to micro-organisms may lead to immune tolerance and hence less recognition to allergens. Various studies have shown that more exposure to micro-organisms during childhood has protective effects against asthma development, for example; growing up in a farm environment, exposure to livestock animals and dogs, drinking unpasteurized milk and breastfeeding all have protective effects on asthma development. [75] [76] [77] [78] [79] However, the limitation to this hypothesis is that it cannot be generalized to all populations. For instance, Japanese individuals are less prone to develop asthma than individuals living in the United States and Australia, 80 despite that they are exposed to a more hygienic environment. 81 The Japanese people have different dietary habits, eat more fermented products and possibly have a microbiome profile that protects them from allergy. Due to the inconsistencies to the hygiene hypothesis found in various studies, a revision has been suggested by the introduction of the "old friend" theory by Rook et al. 82 This theory proposed that micro-organisms co-evolved with humans (old friends) which have been essential for the development of the immune system. 82 Exposure to industrialized environments diminishes these micro-organisms with subsequent defective immune regulation which results in predisposition of the human to chronic inflammatory diseases, such as asthma. Therefore, exposure to natural environments, such as breastfeeding, natural delivery, outdoor activities, healthy-balanced diets and suitable use of antibiotics can re-establish the healthy microbiome environment and consequently reduces risk of allergic disorders. 
| The gut-lung axis and effects on immunity
Gut microbiota produce different types and amounts of short- has shown that the highest levels of butyrate and propionate (>95th percentile) found in the stool of one-year-old infants were later associated with reduced risk of asthma and other allergic disorders at 3 and 6 years of age which might be linked to dietary intake. 88 In a mice study, a high-fibre diet increased levels of circulating SCFAs which decreased susceptibility to allergic airway inflammation, in contrast to low fibre diet which showed the reverse effect. 89 Short-chain fatty acids have affinity for G-protein-coupled receptors such as GPR41, GPR43 and GPR109a, which are known to regulate mucosal immunity. [89] [90] [91] [92] In preclinical and clinical studies, high-fibre diet and SCFAs were found to reduce inflammatory biomarkers and improve lung function through an action mediated through these receptors. 89, 93 In addition to the effects of SCFAs on receptors, butyrate has been shown to act as histone deacetylase inhibitor (HDACi). T H 17 responses and inflammatory process in some tissues including the airways. [97] [98] [99] [100] [101] [102] [103] [104] Bifidobacterium longum was found in higher prevalence in the gut of healthy children (n = 102) compared to those with high risk of allergic asthma and atopic dermatitis (n = 99). 105 Increased abundance of nasopharyngeal lactobacillus was associated with reduced risk of wheezing at two years of age in 118 infants. 106 In the respiratory tract, nasopharyngeal colonization with S pneumoniae and H influenzae leads to increased production of CXCL8 and CXCL2 in nasal lavage fluid of mice, and amplification of asthma-like pro-inflammatory responses.
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A study conducted on the bronchial epithelial brushings of severe asthmatics (n = 40), mild-moderate asthmatics (n = 41) and healthy controls (n = 7) showed that Actinobacteria was correlated with gene expression of FK506 binding protein (FKBP5), which is a marker of corticosteroid responsiveness, while Proteobacteria was correlated with Th17 gene expression. 41 In a study conducted in 8 asthmatics and 6 healthy controls, asthma patients had higher abundance of Proteobacteria, and particularly M catarrhalis was associated with increased expression of inflammatory mediators (eg CCL20, IL1A and IRAK2) and apoptosis (eg TNF and C8orf4). 108, 109 A mice study confirmed the pathogenic role of Proteobacteria inhaled through the nostrils, which induced severe lung inflammation and immunopathology characterized by prevalent airway neutrophilia, and expression of cytokine/chemokine profile. 110 These results are in line with the cross-sectional asthma studies which were discussed previously and imply that increased abundances of certain bacterial taxa, for example Proteobacteria and Firmicutes, and decreased abundances of others, for example Bacteroidetes and Actinobacteria, in asthmatics are probably influencers of asthma disease development, risk and severity.
| THER APEUTI C VALUE OF THE MI CROB I OME IN S I G HTS FOR A S THMA : PRO -B I OTI C , PREB I OTI C AND SYNB I OTI C INTERVENTI ON S
The importance of the microbiota in the asthma disease process has raised interest in the possibility of using dietary supplements influencing the intestinal bacteria, such as pro-biotics 111 and prebiotics 112 and their combinations synbiotics to treat or control asthma. Pro-biotics are "live micro-organisms that, when administered in adequate amounts, confer a health benefit to the host", 111 while prebiotics are "substrates that are selectively utilized by host micro-organisms conferring a health benefit". 112 Synbiotics are combinations of both pro-and prebiotics.
Most evidence of beneficial effects of pro-, pre-and synbiotics comes from animal studies. Mice studies showed that administration of Bifidobacterium breve or adolescentis strains and Lactobacillus plantarum or rhamnosus strains significantly decreased allergic airway inflammation in OVA-or birch pollen-induced asthma mice models. [113] [114] [115] [116] It is worthy to note that the effect of pro-biotics in mice asthma models is more prominent in neonates than adults. 117 One of the available therapeutic options is CpG oligodeoxynucleotides (CpG-ODN) which are synthetic single-stranded DNA that have affinity for TLR9. Mice and other animal (eg cats and rhesus monkeys) studies have shown that CpG-ODN can significantly reduce airway inflammation, hyperreactivity and remodelling [118] [119] [120] [121] [122] [123] [124] and the effect was more pronounced when it was combined with the antigen or used as nanoparticle formulations. 119, 121, 122, 125, 126 In a house dust mite (HDM)-induced asthma mice model, dietary galacto-oligosaccharides were found to prevent airway hyperresponsiveness, airway eosinophilia and T H 2 response, in a comparable way to budesonide 127 and the effect was eliminated in a Treg depleted model which might suggest that it is a Treg cell-mediated response. 128 Synbiotic combination of B breve and non-digestible oligosaccharides was found to have a strong airway anti-inflammatory properties in mice asthma models, 129, 130 and the anti-allergic effect was greater than their individual effects. 131 In contrast to mice studies, little evidence has been found for the beneficial effect of pro-biotics in human asthma. A meta-analysis conducted on 3257 infants from nine randomized clinical trials found that the risk ratio (RR) of asthma in infants received pro-biotics was 133 A randomized controlled trial was conducted on 1,302 asthmatic subjects older than 5 years of age to assess whether pro-biotic intake can reduce antibiotic prescribing for winter respiratory tract infections. 134 In this trial, no significant difference between the intervention group (n = 652) and control group (n = 650) was seen regarding the proportion of participants who were prescribed new courses of antibiotics (odds ratio = 1.04; 95% CI, 0.82-1.34). 134 Despite the diminished effects of pro-biotics shown in human controlled clinical trials, a recent study showed that the delayed gut microbial development in infants with high risk of asthma can be altered with daily oral supplementation of Lactobacillus rhamnosus GG compared with placebo, and this effect was lost 6 months after stopping the supplementation. 135 By changing gut microbial maturation early in infancy, there is a possibility to modify asthma risk later in life. This study provides a new potential strategy for using pro-biotics as an early preventive measure in high-risk infants.
In an open-label trial of 20 adult human asthmatics allergic to HDM, A-type CpG-ODN given as adjuvant to subcutaneous immunotherapy with HMD allergen extract was found to be safe and produce nearly complete alleviation of allergic symptoms after 10 weeks of immunotherapy. 136 In a double-blind trial, where 63 asthmatic patients were treated with 7 injections of either QbG10
(bacteriophage with CpG-motif G10 inside) or placebo, it was found that two-thirds of the intervention group had their asthma well controlled after 12 weeks of treatment compared to one-third of the placebo group. 137 For the effect of prebiotics on humans, a metaanalysis conducted on 249 infants from 2 trials showed that prebiotics reduce the risk of asthma/wheezing compared to the control TA B L E 4 Challenges that interfere for optimum delivery of gained knowledge and therapeutic potential of microbiome and "-biotics" products from bench to bedside
From bench to bedside Challenges Recommendations
Different sampling compartments and whether they are mucosal or luminal should be considered while studying microbiome in asthma
It is important to investigate the microbiome from various sampling compartments in the same studied population and whether drugs (both asthma and non-asthma medications) are associated with microbial changes in certain compartments. Therefore, it might be wise to collect samples from multiple compartments while conducting microbiome asthma studies and adjust for effects introduced by certain medications Different sequencing approaches and platforms might produce variability in reported results
The choice of desired method depends on various factors, such as costs, quality and error rates of the produced sequencing reads. However, investigators should take into account that some of the variability can be introduced by the choice of the sequencing platforms and techniques. Therefore, this is important to consider when comparing results from different studies Some inconsistencies in the reported results have been found in microbiome asthma studies, which might influence clinical applicability and relevance Large multi-centre international microbiome studies, accounting for the effect of multiple possible confounders, should be conducted to reach more definitive conclusions Different ways of reporting studies results, in terms of bacterial taxa, whether at phylum, genus or species level and using specialized microbiological terms can make hindrance for non-expert healthcare professional to see clinical relevance and can produce difficulty to directly compare results between studies
An agreement of clinical experts, stakeholders and healthcare organizations on standardized structure or pattern (as possible) for reporting results of microbiome studies will help to facilitate comparison, interpretation and systematic analysis of the combined work of world-wide research groups Some of the published microbiome asthma studies have investigated the gut microbiome profile without reference to the diet composition or the type of meal the patients usually consume which is an important determinant for the production of SCFAs Accounting for diet while investigating the microbiome should be undertaken in the asthma studies
There is hindrance in the optimum transfer of the therapeutic potential of products targeting microbiota(-biotics) from animal studies to humans A thorough investigation is required to adequately enclose barriers of transmission, and whether personalizing or tailoring "-biotics" to certain patient/groups of patients will show more beneficial effect group (RR = 0.37, 95% CI: 0.17-0.8); however, low number of events made the precision questionable. 138 In summary, mice studies show promising results of using pro-, pre-and synbiotics in asthma models, while evidence in humans is scarce, especially for pro-biotics. One possibility for decreased therapeutic outcomes in infants is that the intended therapeutic outcomes are long term (for years) which can be influenced by different factors, such as environmental exposure, different dietary habits and dynamicity of microbiome over time. Whether the individual should receive high-fibre diet or making certain diet restrictions should be also considered in clinical trials of pro-biotics. New strategies for using products targeting the microbiota to prevent or treat asthma should be further investigated. Moreover, the role of precision medicine is very important to define certain individuals or patients' groups who can benefit most from the potential therapeutic "-biotics" options.
| THE A S THMA MI CROB I OME FROM B EN CH TO B EDS IDE: CHALLENG E S
Results of microbiome studies in patients with asthma convey the importance of the role of microbiome either in the intestinal tract or in the airways in shaping asthma. However, using combined information from different studies to elaborate the asthma-microbiome interaction in humans is hindered by methodological, design and interpretations issues/challenges in microbiome studies (Table 4) . We suggest some recommendations to overcome them.
More efforts are required from healthcare professionals and researchers to conduct large-scale microbiome asthma studies, if possible, accounting for and/or minimizing sources of variability, to obtain a clearer overview of the microbiome role in asthma. We still do not clearly know the type of link between reported microbial dysbiosis and different asthma characteristics; whether is it an association or causation? And what is the direction in case of the latter? The finding that early life microbial dysbiosis was associated with increased risk of asthma later in life might suggest that the microbiome is responsible to some extent to asthma disease development. However, this does not negate that the link might be bidirectional. More research is needed to investigate the relationship behind just "associations."
Translating the results of microbiome asthma studies from sequencing reads into applicable clinical guidelines requires a systematic approach and cooperation of multi-disciplinary research groups.
One strategy is to use the microbiome to better refine asthma phenotypes (eg neutrophilic asthma) diagnosis, for which certain therapeutics targets might be directed. Another strategy is to detect groups of asthma patients with clear microbial dysbiosis for whom interventions (eg pre-, pro-and synbiotics) to reshape the gut and/or airway microbiome might be more beneficial.
The microbiome is thought to have host genetic background, 139 cause epigenetic modulations, 140 affect host metabolism 141 and be influenced by environmental exposures. 142 This necessitates integrating the microbiome with other omics layers, such as metabolomics, proteomics, transcriptomics, genomics, epigenomics and exposomics (environmental factors), which will help to provide more insight into the mechanisms of complex disease processes such as asthma. Hopefully, this will aid to discover new biomarkers for better diagnosis and/or new therapeutic targets in asthmatic patients. org/0000-0002-0414-3442
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